Last updated: February 20, 2026
What Are Calcimimetic Agents?
Calcimimetic agents activate calcium-sensing receptors (CaSR) on the parathyroid gland. They reduce parathyroid hormone (PTH) secretion, making them effective in treating secondary hyperparathyroidism and some forms of primary hyperparathyroidism, especially in patients with chronic kidney disease (CKD). The primary drugs include cinacalcet and etelcalcetide.
Market Overview
Market Size and Growth
The global calcimimetic agents market reached approximately $1.2 billion in 2022, with a compound annual growth rate (CAGR) of 5.2% projected through 2030. Growth drivers include increasing prevalence of CKD, expanding indications, and technological advances.
| Year |
Market Size (USD billion) |
CAGR |
Key Drivers |
| 2022 |
1.2 |
5.2% |
Rising CKD cases, improved diagnosis |
| 2023 |
1.26 |
- |
Market expansion |
| 2024 |
1.32 |
- |
New formulations, biosimilar entry |
Key Market Segments
-
Indications:
- Secondary hyperparathyroidism in CKD patients on dialysis (~85% of sales)
- Primary hyperparathyroidism (~10%)
- Other (e.g., PNET syndromes, experimental uses)
-
Geography:
- North America: 45%
- Europe: 30%
- Asia-Pacific: 20%
- Others: 5%
Major Players
| Company |
Drug |
Revenue (2022) |
Market Share |
Pipeline Status |
| Amgen |
etelcalcetide |
$600 million |
50% |
Approved, in phase 3 trials for other indications |
| TJU (generic) |
cinacalcet |
$600 million |
50% |
Established, patent expiry ongoing in 2025 |
Patent Landscape
Patent Timeline
- Cinacalcet: Patents filed from 1997-2000; key patents expiring between 2025 and 2027.
- Etelcalcetide: Approved in 2017; key patents filed 2004-2008, expiring around 2030.
Patent Types and Coverage
- Composition of matter patents: Cover the chemical structure of cinacalcet and etelcalcetide.
- Method of use patents: Cover specific treatment methods for hyperparathyroidism.
- Formulation patents: Cover different formulations, extended to 2030 for some patents.
- Manufacturing process patents: Limited in scope, mostly expired or close to expiry.
Patent Risks and Opportunities
- Patent expiries of key drugs pressure R&D investments on biosimilars and generics.
- Patent filings in Asia-Pacific and emerging markets increase competition.
- Biosimilars of etelcalcetide are in early development stages, with potential to erode revenue.
Legal and Regulatory Environment
- US FDA, EMA, and other agencies review patents and exclusivity periods.
- Patent litigation involves infringement cases and patent term extensions.
- Data exclusivity adds an additional layer of market protection.
Competitive Landscape
| Company |
Strategy |
Pipeline Highlights |
Challenges |
| Amgen |
Expand indications, improve formulations |
New formulations for existing drugs |
Patent cliff, biosimilar entry |
| Generic Manufacturers |
Enter post-patent expiry |
Biosimilars in early phases |
Regulatory hurdles, market access |
| Innovators |
Develop next-generation calcimimetics |
Novel agents targeting CaSR |
High R&D costs, clinical validation required |
Regulatory Trends
- Accelerated approval pathways in the US, like Fast Track, facilitate faster market entry.
- Post-market data collection influences patent exclusivity extensions.
- The increasing use of biosimilars is governed by strict biosimilar approval pathways in the US and EU.
Key Takeaways
- The calcimimetic agents market is driven by CKD prevalence, with growth projections supported by expanding indications and developing markets.
- Patents for the leading drugs, cinacalcet and etelcalcetide, expire around 2025-2030, opening opportunities for generics and biosimilars.
- Patent challenges focus on composition of matter and method patents, with recent filings extending patent life.
- The shift toward biosimilars is promising but faces regulatory and market entry hurdles.
- Competition is intensifying in emerging markets with patent expiries and biosimilar development.
FAQs
1. When do key patents for cinacalcet expire?
Patents filed between 1997-2000 are expiring from 2025 to 2027, with some patent extensions possible until 2027.
2. What are the main drivers of growth in the calcimimetic market?
Increasing CKD prevalence, broader indications, and introduction of biosimilars and new formulations.
3. Are biosimilars likely to impact revenue significantly?
Yes, especially after patent expiry, with biosimilar development underway, though regulatory and clinical challenges remain.
4. What regional market presents the highest growth potential?
Asia-Pacific offers high growth due to expanding healthcare infrastructure and increasing CKD diagnoses.
5. How does patent litigation influence the market?
Legal disputes may delay biosimilar entry or extend exclusivity via patent extensions, shaping competitive dynamics.
References
[1] MarketsandMarkets. (2023). Calcimimetic Agents Market Size, Share & Trends.
[2] U.S. Food and Drug Administration. (2022). Calcimimetic Drugs Data & Approvals.
[3] European Medicines Agency. (2022). Medicinal Chemistry & Patent Reports.
[4] Pharma Intelligence. (2022). Patent Expiry Reports for Hyperparathyroidism Drugs.
[5] World Health Organization. (2022). Global CKD and Hyperparathyroidism Statistics.
